These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 22596349)

  • 1. Poly(ADP-ribose) polymerase 1 modulates the lethality of CHK1 inhibitors in mammary tumors.
    Tang Y; Hamed HA; Poklepovic A; Dai Y; Grant S; Dent P
    Mol Pharmacol; 2012 Aug; 82(2):322-32. PubMed ID: 22596349
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Poly(ADP-ribose) polymerase 1 modulates the lethality of CHK1 inhibitors in carcinoma cells.
    Mitchell C; Park M; Eulitt P; Yang C; Yacoub A; Dent P
    Mol Pharmacol; 2010 Nov; 78(5):909-17. PubMed ID: 20696794
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PARP and CHK inhibitors interact to cause DNA damage and cell death in mammary carcinoma cells.
    Booth L; Cruickshanks N; Ridder T; Dai Y; Grant S; Dent P
    Cancer Biol Ther; 2013 May; 14(5):458-65. PubMed ID: 23917378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Response of subtype-specific human breast cancer-derived cells to poly(ADP-ribose) polymerase and checkpoint kinase 1 inhibition.
    Shibata H; Miuma S; Saldivar JC; Huebner K
    Cancer Sci; 2011 Oct; 102(10):1882-8. PubMed ID: 21707865
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors.
    Du Y; Yamaguchi H; Wei Y; Hsu JL; Wang HL; Hsu YH; Lin WC; Yu WH; Leonard PG; Lee GR; Chen MK; Nakai K; Hsu MC; Chen CT; Sun Y; Wu Y; Chang WC; Huang WC; Liu CL; Chang YC; Chen CH; Park M; Jones P; Hortobagyi GN; Hung MC
    Nat Med; 2016 Feb; 22(2):194-201. PubMed ID: 26779812
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Poly(ADP-ribose) binding to Chk1 at stalled replication forks is required for S-phase checkpoint activation.
    Min W; Bruhn C; Grigaravicius P; Zhou ZW; Li F; Krüger A; Siddeek B; Greulich KO; Popp O; Meisezahl C; Calkhoven CF; Bürkle A; Xu X; Wang ZQ
    Nat Commun; 2013; 4():2993. PubMed ID: 24356582
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The CHK1 inhibitor SRA737 synergizes with PARP1 inhibitors to kill carcinoma cells.
    Booth L; Roberts J; Poklepovic A; Dent P
    Cancer Biol Ther; 2018; 19(9):786-796. PubMed ID: 30024813
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhancing CHK1 inhibitor lethality in glioblastoma.
    Tang Y; Dai Y; Grant S; Dent P
    Cancer Biol Ther; 2012 Apr; 13(6):379-88. PubMed ID: 22313687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Poly (ADP-ribose) polymerases inhibitor, Zj6413, as a potential therapeutic agent against breast cancer.
    Zhou Q; Ji M; Zhou J; Jin J; Xue N; Chen J; Xu B; Chen X
    Biochem Pharmacol; 2016 May; 107():29-40. PubMed ID: 26920250
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials.
    Yuan B; Ye N; Song SS; Wang YT; Song Z; Chen HD; Chen CH; Huan XJ; Wang YQ; Su Y; Shen YY; Sun YM; Yang XY; Chen Y; Guo SY; Gan Y; Gao ZW; Chen XY; Ding J; He JX; Zhang A; Miao ZH
    Cancer Lett; 2017 Feb; 386():47-56. PubMed ID: 27847302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapamycin-resistant poly (ADP-ribose) polymerase-1 overexpression is a potential therapeutic target in lymphangioleiomyomatosis.
    Sun Y; Gallacchi D; Zhang EY; Reynolds SB; Robinson L; Malinowska IA; Chiou TT; Pereira AM; Li C; Kwiatkowski DJ; Lee PS; Yu JJ
    Am J Respir Cell Mol Biol; 2014 Dec; 51(6):738-49. PubMed ID: 24874429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective radiosensitization of p53 mutant pancreatic cancer cells by combined inhibition of Chk1 and PARP1.
    Vance S; Liu E; Zhao L; Parsels JD; Parsels LA; Brown JL; Maybaum J; Lawrence TS; Morgan MA
    Cell Cycle; 2011 Dec; 10(24):4321-9. PubMed ID: 22134241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced killing of cancer cells by poly(ADP-ribose) polymerase inhibitors and topoisomerase I inhibitors reflects poisoning of both enzymes.
    Patel AG; Flatten KS; Schneider PA; Dai NT; McDonald JS; Poirier GG; Kaufmann SH
    J Biol Chem; 2012 Feb; 287(6):4198-210. PubMed ID: 22158865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simultaneous exposure of transformed cells to SRC family inhibitors and CHK1 inhibitors causes cell death.
    Mitchell C; Hamed HA; Cruickshanks N; Tang Y; Bareford MD; Hubbard N; Tye G; Yacoub A; Dai Y; Grant S; Dent P
    Cancer Biol Ther; 2011 Aug; 12(3):215-28. PubMed ID: 21642769
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The preclinical pharmacology and therapeutic activity of the novel CHK1 inhibitor SAR-020106.
    Walton MI; Eve PD; Hayes A; Valenti M; De Haven Brandon A; Box G; Boxall KJ; Aherne GW; Eccles SA; Raynaud FI; Williams DH; Reader JC; Collins I; Garrett MD
    Mol Cancer Ther; 2010 Jan; 9(1):89-100. PubMed ID: 20053762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency.
    Shen Y; Rehman FL; Feng Y; Boshuizen J; Bajrami I; Elliott R; Wang B; Lord CJ; Post LE; Ashworth A
    Clin Cancer Res; 2013 Sep; 19(18):5003-15. PubMed ID: 23881923
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Small molecule inhibition of the CHFR-PARP1 interaction as novel approach to overcome intrinsic taxane resistance in cancer.
    Brodie SA; Li G; Harvey D; Khuri FR; Vertino PM; Brandes JC
    Oncotarget; 2015 Oct; 6(31):30773-86. PubMed ID: 26356822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of potent 2,4-difluoro-linker poly(ADP-ribose) polymerase 1 inhibitors with enhanced water solubility and in vivo anticancer efficacy.
    Chen WH; Song SS; Qi MH; Huan XJ; Wang YQ; Jiang H; Ding J; Ren GB; Miao ZH; Li J
    Acta Pharmacol Sin; 2017 Nov; 38(11):1521-1532. PubMed ID: 28770827
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Poly-ADP-Ribose Polymerase as a Therapeutic Target in Pediatric Diffuse Intrinsic Pontine Glioma and Pediatric High-Grade Astrocytoma.
    Chornenkyy Y; Agnihotri S; Yu M; Buczkowicz P; Rakopoulos P; Golbourn B; Garzia L; Siddaway R; Leung S; Rutka JT; Taylor MD; Dirks PB; Hawkins C
    Mol Cancer Ther; 2015 Nov; 14(11):2560-8. PubMed ID: 26351319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological Inhibition of PARP6 Triggers Multipolar Spindle Formation and Elicits Therapeutic Effects in Breast Cancer.
    Wang Z; Grosskurth SE; Cheung T; Petteruti P; Zhang J; Wang X; Wang W; Gharahdaghi F; Wu J; Su N; Howard RT; Mayo M; Widzowski D; Scott DA; Johannes JW; Lamb ML; Lawson D; Dry JR; Lyne PD; Tate EW; Zinda M; Mikule K; Fawell SE; Reimer C; Chen H
    Cancer Res; 2018 Dec; 78(23):6691-6702. PubMed ID: 30297535
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.